,Gene,Gene synonym,Ensembl,Gene description,Chromosome,Position,Protein class,Evidence,Antibody,Reliability (IH),Reliability (Mouse Brain),Reliability (IF),Subcellular location,Prognostic p-value,RNA cancer category,RNA tissue category,RNA TS,RNA TS TPM,TPM max in non-specific,RNA cell line category,RNA CS,RNA CS TPM
0,ABHD16A,"BAT5, D6S82E, NG26",ENSG00000204427,Abhydrolase domain containing 16A,6,31686949-31703444,Predicted membrane proteins,Evidence at protein level,HPA058606,Approved,,,,Endometrial cancer:2.63e-4 (unfavourable),Expressed in all,Tissue enhanced,,gallbladder: 1.7;testis: 1.2;thyroid gland: 1.4,esophagus: 0.9,Not detected,,
1,ADAMTS14,,ENSG00000138316,ADAM metallopeptidase with thrombospondin type 1 motif 14,10,70672803-70762441,"Cancer-related genes, Plasma proteins, Predicted secreted proteins",Evidence at protein level,HPA034605,,,Uncertain,Cytosol,,Mixed,Tissue enhanced,,gallbladder: 10.9;placenta: 11.1,urinary bladder: 4.4,Cell line enhanced,,CAPAN-2: 8.0;K-562: 9.5;RH-30: 5.3;U-138 MG: 8.8
2,ADAMTS16,ADAMTS16s,ENSG00000145536,ADAM metallopeptidase with thrombospondin type 1 motif 16,5,5140330-5320304,Predicted secreted proteins,Evidence at protein level,,,,,,Renal cancer:3.29e-5 (favourable),Mixed,Tissue enhanced,,gallbladder: 9.9;ovary: 11.2,adipose tissue: 6.3,Cell line enhanced,,hTEC/SVTERT24-B: 3.9;U-2197: 5.3
3,ADCYAP1,PACAP,ENSG00000141433,Adenylate cyclase activating polypeptide 1,18,904943-912172,Predicted secreted proteins,Evidence at protein level,HPA065887,,Approved,,,Renal cancer:2.91e-6 (favourable),Tissue enhanced,Tissue enhanced,,appendix: 19.3;cerebral cortex: 16.0;gallbladder: 15.7,testis: 5.6,Cell line enriched,17.0,SCLC-21H: 20.8
4,AKR1B10,"AKR1B11, AKR1B12, ALDRLn, ARL-1, ARL1, HIS, HSI",ENSG00000198074,Aldo-keto reductase family 1 member B10,7,134527592-134541408,Predicted intracellular proteins,Evidence at protein level,"HPA020280, CAB070163, HPA073633",Enhanced,,Supported,Plasma membrane<br>Cytosol,"Renal cancer:4.80e-9 (unfavourable), Colorectal cancer:1.91e-4 (favourable)",Tissue enhanced,Tissue enhanced,,duodenum: 635.9;gallbladder: 283.3;small intestine: 387.2;stomach: 414.4,esophagus: 89.8,Group enriched,74.0,A549: 2731.1;Hep G2: 580.9
5,ALKAL1,"AUGB, FAM150A, UNQ9433",ENSG00000196711,ALK and LTK ligand 1,8,52534037-52565507,Predicted secreted proteins,Evidence at protein level,HPA027368,Uncertain,,,,,Mixed,Tissue enhanced,,gallbladder: 3.5;thyroid gland: 3.6,"cervix, uterine: 1.7",Cell line enhanced,,CAPAN-2: 1.1
6,ARL14,"ARF7, FLJ22595",ENSG00000179674,ADP ribosylation factor like GTPase 14,3,160677159-160678452,Predicted intracellular proteins,Evidence at protein level,,,,,,"Lung cancer:2.64e-5 (unfavourable), Pancreatic cancer:6.71e-4 (unfavourable)",Group enriched,Tissue enhanced,,gallbladder: 209.1;stomach: 70.2,duodenum: 50.9,Group enriched,5.0,A-431: 8.4;CAPAN-2: 31.7;HaCaT: 7.9;RT4: 14.0
7,B3GALT2,beta3Gal-T2,ENSG00000162630,"Beta-1,3-galactosyltransferase 2",1,193179045-193186654,"Enzymes, Predicted membrane proteins",Evidence at protein level,,,,,,,Tissue enhanced,Tissue enhanced,,cerebral cortex: 29.0;gallbladder: 26.0,heart muscle: 14.9,Group enriched,5.0,AF22: 19.6;ASC TERT1: 6.1;LHCN-M2: 11.4;WM-115: 23.5
8,BDKRB1,"B1BKR, BKR1, bradyb1",ENSG00000100739,Bradykinin receptor B1,14,96255824-96268967,"G-protein coupled receptors, Predicted membrane proteins",Evidence at protein level,HPA002935,Approved,,,,,Mixed,Tissue enhanced,,gallbladder: 18.2,urinary bladder: 9.9,Cell line enhanced,,BJ hTERT+: 19.8;HHSteC: 20.3;hTEC/SVTERT24-B: 23.1;U-2197: 23.8;U-87 MG: 82.4
9,C11orf91,,ENSG00000205177,Chromosome 11 open reading frame 91,11,33698261-33700801,Predicted intracellular proteins,Evidence at protein level,"HPA047064, HPA050487",Uncertain,,Supported,Vesicles,,Not detected,Tissue enhanced,,adipose tissue: 5.8;gallbladder: 7.7;testis: 6.9,esophagus: 3.3,Cell line enhanced,,HBEC3-KT: 11.7;hTERT-HME1: 7.8;HUVEC TERT2: 6.8;TIME: 10.3;U-2197: 9.7
10,C14orf105,FLJ10650,ENSG00000100557,Chromosome 14 open reading frame 105,14,57469301-57493867,Predicted intracellular proteins,Evidence at transcript level,HPA029202,,,Uncertain,Nucleus<br>Cytosol,"Renal cancer:1.92e-4 (favourable), Liver cancer:5.61e-4 (unfavourable)",Tissue enhanced,Tissue enhanced,,fallopian tube: 43.7;gallbladder: 27.1;kidney: 63.6,liver: 11.3,Group enriched,6.0,A549: 10.7;RPTEC TERT1: 26.1
11,C6orf141,MGC46457,ENSG00000197261,Chromosome 6 open reading frame 141,6,49550646-49561907,Predicted intracellular proteins,Evidence at protein level,HPA036199,Uncertain,,Approved,Nuclear membrane,"Breast cancer:3.92e-6 (favourable), Endometrial cancer:1.15e-4 (favourable)",Mixed,Tissue enhanced,,gallbladder: 9.3,duodenum: 6.2,Cell line enhanced,,HaCaT: 7.6;PC-3: 10.6;T-47d: 6.8
12,CA9,"CAIX, MN",ENSG00000107159,Carbonic anhydrase 9,9,35673856-35681159,"Enzymes, Predicted membrane proteins, Predicted secreted proteins",Evidence at protein level,"CAB005100, CAB017107, HPA055207",Enhanced,,Enhanced,Plasma membrane<br>Cytosol,"Renal cancer:2.22e-7 (unfavourable), Liver cancer:1.71e-5 (unfavourable), Testis cancer:9.50e-4 (favourable)",Mixed,Tissue enhanced,,gallbladder: 36.0;stomach: 93.6,small intestine: 14.5,Group enriched,11.0,A-431: 152.1;HDLM-2: 84.3;U-87 MG: 337.9
13,CCL20,"CKb4, exodus-1, LARC, MIP-3a, SCYA20, ST38",ENSG00000115009,C-C motif chemokine ligand 20,2,227813842-227817564,Predicted secreted proteins,Evidence at protein level,,,,,,"Renal cancer:9.19e-8 (unfavourable), Pancreatic cancer:2.73e-4 (unfavourable), Liver cancer:9.29e-4 (unfavourable)",Expressed in all,Tissue enhanced,,gallbladder: 269.7;tonsil: 155.2,urinary bladder: 83.4,Cell line enhanced,,Hep G2: 23.9;NB-4: 12.7;RT4: 12.0
14,CFTR,"ABC35, ABCC7, CF, CFTR/MRP, dJ760C5.1, MRP7, TNR-CFTR",ENSG00000001626,Cystic fibrosis transmembrane conductance regulator,7,117465784-117715971,"Cancer-related genes, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Transporters",Evidence at protein level,"CAB001951, HPA021939",Enhanced,,,,Liver cancer:9.44e-4 (unfavourable),Tissue enhanced,Tissue enhanced,,gallbladder: 89.3,rectum: 49.0,Group enriched,19.0,CACO-2: 26.2;MOLT-4: 97.6;U-266/70: 47.9
15,CHRM2,,ENSG00000181072,Cholinergic receptor muscarinic 2,7,136868669-137020255,"Disease related genes, FDA approved drug targets, G-protein coupled receptors, Predicted membrane proteins",Evidence at protein level,"CAB022338, HPA029795",Approved,,,,,Tissue enhanced,Tissue enhanced,,gallbladder: 18.3;heart muscle: 25.8;smooth muscle: 13.7,urinary bladder: 5.9,Cell line enhanced,,BJ: 14.1;BJ hTERT+: 15.2;fHDF/TERT166: 71.3;HHSteC: 10.8
16,CILP2,MGC45771,ENSG00000160161,Cartilage intermediate layer protein 2,19,19538248-19546659,Predicted secreted proteins,Evidence at protein level,HPA041847,Uncertain,,,,"Endometrial cancer:3.22e-6 (unfavourable), Ovarian cancer:2.50e-4 (unfavourable)",Mixed,Tissue enhanced,,gallbladder: 2.5;testis: 4.2,adipose tissue: 0.8,Cell line enhanced,,ASC diff: 3.2;HEK93: 2.6
17,CLCF1,"BSF-3, BSF3, CISS2, CLC, NNT-1, NNT1, NR6",ENSG00000175505,Cardiotrophin-like cytokine factor 1,11,67364168-67374177,"Disease related genes, Predicted secreted proteins",Evidence at protein level,HPA042444,Uncertain,,Approved,Nuclear bodies<br>Vesicles,,Expressed in all,Tissue enhanced,,gallbladder: 26.3,endometrium: 21.4,Cell line enhanced,,SiHa: 56.8
18,CLDN2,,ENSG00000165376,Claudin 2,X,106900164-106930861,Predicted membrane proteins,Evidence at protein level,"CAB002609, HPA051548",Enhanced,,Supported,Nucleoplasm<br>Cell Junctions,Thyroid cancer:1.70e-4 (favourable),Group enriched,Tissue enhanced,,gallbladder: 159.0;kidney: 171.8;seminal vesicle: 129.3,epididymis: 41.1,Group enriched,23.0,A549: 24.6;CACO-2: 18.2;RPTEC TERT1: 35.1
19,CNTNAP5,"caspr5, FLJ31966",ENSG00000155052,Contactin associated protein like 5,2,124025287-124915287,Predicted membrane proteins,Evidence at protein level,"HPA069095, HPA069356",,,Supported,Nucleus<br>Nucleoli fibrillar center<br>Vesicles,,Tissue enhanced,Tissue enhanced,,cerebral cortex: 5.8;gallbladder: 1.6,adrenal gland: 0.7,Cell line enhanced,,AF22: 1.1;SH-SY5Y: 2.8
20,COL10A1,,ENSG00000123500,Collagen type X alpha 1 chain,6,116118923-116158747,"Disease related genes, Predicted secreted proteins",Evidence at protein level,HPA053268,,,Approved,Endoplasmic reticulum,,Tissue enhanced,Tissue enhanced,,gallbladder: 14.5,ovary: 4.9,Cell line enriched,6.0,hTEC/SVTERT24-B: 39.7
21,COL3A1,EDS4A,ENSG00000168542,Collagen type III alpha 1 chain,2,188974320-189012746,"Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins",Evidence at protein level,"HPA007583, CAB016766, CAB059993",Approved,,,,Renal cancer:3.59e-10 (unfavourable),Expressed in all,Tissue enhanced,,"cervix, uterine: 3796.7;gallbladder: 3334.2;smooth muscle: 3029.8",placenta: 2768.0,Cell line enhanced,,AF22: 1344.2;ASC diff: 1690.4;ASC TERT1: 2979.5;fHDF/TERT166: 1406.5;HHSteC: 1419.6;HSkMC: 2318.4
22,COLEC11,"CL-K1, MGC3279",ENSG00000118004,Collectin subfamily member 11,2,3594832-3644644,"Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins",Evidence at protein level,HPA035241,Approved,,,,,Tissue enhanced,Tissue enhanced,,gallbladder: 102.0,adrenal gland: 36.2,Group enriched,8.0,HHSteC: 135.6;SH-SY5Y: 158.1
23,COMP,"EDM1, EPD1, MED, PSACH, THBS5",ENSG00000105664,Cartilage oligomeric matrix protein,19,18782773-18791314,"Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins",Evidence at protein level,HPA077555,,,Approved,Golgi apparatus,"Renal cancer:1.52e-6 (unfavourable), Colorectal cancer:9.08e-5 (unfavourable), Endometrial cancer:2.04e-4 (unfavourable), Urothelial cancer:6.95e-4 (unfavourable)",Mixed,Tissue enhanced,,gallbladder: 24.5,smooth muscle: 18.2,Cell line enriched,5.0,fHDF/TERT166: 666.2
24,CPA3,,ENSG00000163751,Carboxypeptidase A3,3,148865256-148897196,"Enzymes, Plasma proteins, Predicted secreted proteins",Evidence at protein level,"HPA006479, HPA008689, CAB020712",Enhanced,,,,,Mixed,Tissue enhanced,,gallbladder: 173.9,lung: 126.9,Cell line enriched,46.0,HEL: 265.9
25,CPXM1,"CPX-1, CPX1, CPXM",ENSG00000088882,"Carboxypeptidase X, M14 family member 1",20,2794069-2800637,"Enzymes, Predicted secreted proteins",Evidence at protein level,,,,,,Renal cancer:4.62e-10 (unfavourable),Expressed in all,Tissue enhanced,,endometrium: 130.4;gallbladder: 132.2,urinary bladder: 75.0,Group enriched,5.0,AF22: 158.5;HSkMC: 62.0;NB-4: 92.9;NTERA-2: 34.2;REH: 136.3;SH-SY5Y: 113.9
26,CRLF2,"CRL2, TSLPR",ENSG00000205755,Cytokine receptor-like factor 2,X,1187549-1212750,"Cancer-related genes, Predicted membrane proteins",Evidence at protein level,,,,,,,Tissue enhanced,Tissue enhanced,,appendix: 2.1;gallbladder: 2.0,bone marrow: 1.0,Cell line enhanced,,HMC-1: 13.5;RPMI-8226: 2.8;U-698: 2.4
27,CSMD2,KIAA1884,ENSG00000121904,CUB and Sushi multiple domains 2,1,33513999-34165842,"Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,HPA008622,Uncertain,,,,,Tissue enhanced,Tissue enhanced,,cerebral cortex: 2.6;gallbladder: 1.8,testis: 1.0,Cell line enhanced,,fHDF/TERT166: 5.3;HEL: 9.4;NTERA-2: 8.1;PC-3: 7.8;U-87 MG: 23.1
28,CTHRC1,,ENSG00000164932,Collagen triple helix repeat containing 1,8,103371515-103382997,"Disease related genes, Predicted intracellular proteins, Predicted secreted proteins",Evidence at protein level,"HPA059806, HPA061896",Approved,,Approved,Nucleoplasm,"Renal cancer:1.22e-14 (unfavourable), Liver cancer:1.67e-4 (unfavourable)",Expressed in all,Tissue enhanced,,gallbladder: 137.8;placenta: 125.5;urinary bladder: 100.0,breast: 49.2,Cell line enhanced,,ASC TERT1: 202.9;HHSteC: 162.6;HSkMC: 291.0;WM-115: 375.8
29,CXCL6,"CKA-3, GCP-2, SCYB6",ENSG00000124875,C-X-C motif chemokine ligand 6,4,73836497-73849064,Predicted secreted proteins,Evidence at protein level,,,,,,Renal cancer:4.82e-4 (unfavourable),Mixed,Tissue enhanced,,gallbladder: 50.3;spleen: 112.9,urinary bladder: 32.4,Group enriched,6.0,BJ hTERT+: 36.7;EFO-21: 100.3;hTEC/SVTERT24-B: 22.6;HUVEC TERT2: 59.0;RPTEC TERT1: 62.9
30,CYP4F11,,ENSG00000171903,Cytochrome P450 family 4 subfamily F member 11,19,15912367-15934867,"Enzymes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins",Evidence at protein level,"HPA017265, CAB033648, HPA058960",Enhanced,,,,"Breast cancer:4.05e-4 (favourable), Pancreatic cancer:9.28e-4 (unfavourable)",Mixed,Tissue enhanced,,gallbladder: 29.5;liver: 32.7;small intestine: 26.3,epididymis: 20.0,Cell line enhanced,,A-431: 11.4;CAPAN-2: 44.2;EFO-21: 17.4;Hep G2: 17.0;RT4: 12.1
31,DEPDC1B,"BRCC3, XTP1",ENSG00000035499,DEP domain containing 1B,5,60596912-60700190,Predicted intracellular proteins,Evidence at protein level,"HPA038255, HPA072558",Approved,,Approved,Nucleoplasm<br>Golgi apparatus<br>Cytosol,"Lung cancer:6.93e-5 (unfavourable), Colorectal cancer:2.42e-4 (favourable), Liver cancer:3.08e-4 (unfavourable), Endometrial cancer:8.55e-4 (unfavourable)",Expressed in all,Tissue enhanced,,gallbladder: 33.0;testis: 22.6,lymph node: 10.8,Mixed,,
32,DUOX2,"LNOX2, P138-TOX, P138(TOX), THOX2",ENSG00000140279,Dual oxidase 2,15,45092650-45114344,"Disease related genes, Enzymes, Potential drug targets, Predicted membrane proteins, Transporters",Evidence at protein level,,,,,,,Tissue enhanced,Tissue enhanced,,gallbladder: 446.7;thyroid gland: 124.8,urinary bladder: 87.1,Cell line enriched,8.0,HaCaT: 5.5
33,DUOXA2,,ENSG00000140274,Dual oxidase maturation factor 2,15,45114321-45118421,"Disease related genes, Predicted membrane proteins",Evidence at protein level,HPA063548,Enhanced,,,,,Group enriched,Tissue enhanced,,gallbladder: 97.3;urinary bladder: 24.7,thyroid gland: 13.6,Cell line enhanced,,U-2 OS: 1.0
34,ERICH5,"C8orf47, FLJ39553",ENSG00000177459,Glutamate rich 5,8,98064311-98093610,Predicted intracellular proteins,Evidence at protein level,"HPA025070, HPA025293, HPA027233",Enhanced,,Approved,Nucleoplasm<br>Golgi apparatus<br>Cytosol,"Renal cancer:3.76e-4 (favourable), Urothelial cancer:9.38e-4 (favourable)",Tissue enhanced,Tissue enhanced,,fallopian tube: 13.8;gallbladder: 13.7,stomach: 9.2,Cell line enhanced,,A549: 6.1;HAP1: 6.4;HEK93: 8.2;RT4: 12.7
35,F2RL2,PAR3,ENSG00000164220,Coagulation factor II thrombin receptor like 2,5,76615482-76623434,"G-protein coupled receptors, Predicted membrane proteins",Evidence at protein level,,,,,,Colorectal cancer:4.69e-4 (favourable),Mixed,Tissue enhanced,,gallbladder: 10.9,smooth muscle: 5.6,Cell line enhanced,,BJ hTERT+: 43.2;HEL: 65.9;hTEC/SVTERT24-B: 34.7;U-138 MG: 52.8;WM-115: 67.6
36,FAM180A,"HWKM1940, UNQ1940",ENSG00000189320,Family with sequence similarity 180 member A,7,135728348-135748846,Predicted secreted proteins,Evidence at protein level,HPA021224,Uncertain,,,,,Mixed,Tissue enhanced,,gallbladder: 25.5,heart muscle: 10.4,Cell line enhanced,,BJ hTERT+: 45.6;fHDF/TERT166: 44.5;U-138 MG: 55.9;U-2197: 239.9
37,FGF5,,ENSG00000138675,Fibroblast growth factor 5,4,80266599-80336680,"Disease related genes, Predicted secreted proteins, RAS pathway related proteins",Evidence at protein level,"CAB010313, HPA042442",,,Supported,Nucleus<br>Nucleoli fibrillar center<br>Cytosol,,Not detected,Tissue enhanced,,gallbladder: 5.6,smooth muscle: 1.4,Cell line enhanced,,BJ hTERT+: 97.8;fHDF/TERT166: 68.3;HBF TERT88: 85.6;LHCN-M2: 67.6;U-138 MG: 108.3
38,FGF7,KGF,ENSG00000140285,Fibroblast growth factor 7,15,49423096-49488775,"Cancer-related genes, Predicted intracellular proteins, Predicted secreted proteins, RAS pathway related proteins",Evidence at protein level,HPA043605,Uncertain,,Approved,Nucleus<br>Nucleoli,,Mixed,Tissue enhanced,,gallbladder: 55.0,endometrium: 31.1,Cell line enhanced,,ASC diff: 31.5;ASC TERT1: 29.3;HSkMC: 31.1;RH-30: 33.7;U-138 MG: 23.1
39,FNDC1,"bA243O10.1, dJ322A24.1, FNDC2, KIAA1866",ENSG00000164694,Fibronectin type III domain containing 1,6,159169397-159272109,"Predicted intracellular proteins, Predicted secreted proteins",Evidence at protein level,"HPA030962, HPA030963",Approved,,Supported,Nuclear speckles,"Renal cancer:1.93e-6 (unfavourable), Endometrial cancer:6.10e-5 (favourable)",Tissue enhanced,Tissue enhanced,,gallbladder: 22.9;thyroid gland: 34.1,smooth muscle: 16.5,Cell line enhanced,,fHDF/TERT166: 2.3
40,FOSL1,fra-1,ENSG00000175592,"FOS like 1, AP-1 transcription factor subunit",11,65892049-65900573,"Cancer-related genes, Plasma proteins, Predicted intracellular proteins, Transcription factors",Evidence at protein level,"CAB004396, HPA066901",Uncertain,,Enhanced,Nucleoplasm,"Renal cancer:6.40e-6 (unfavourable), Pancreatic cancer:9.26e-5 (unfavourable), Lung cancer:1.95e-4 (unfavourable), Head and neck cancer:2.05e-4 (unfavourable), Glioma:2.46e-4 (unfavourable)",Expressed in all,Tissue enhanced,,adipose tissue: 35.6;gallbladder: 51.7,urinary bladder: 26.8,Cell line enhanced,,PC-3: 759.0;WM-115: 1227.8
41,FOXL1,"FKH6, FKHL11, FREAC7",ENSG00000176678,Forkhead box L1,16,86576368-86582160,"Predicted intracellular proteins, Transcription factors",Evidence at transcript level,,,,,,,Tissue enhanced,Tissue enhanced,,gallbladder: 8.3,duodenum: 3.1,Cell line enhanced,,CAPAN-2: 33.6;PC-3: 45.9;U-87 MG: 104.7
42,GCNT3,"C2/4GnT, C2GnT-M, C2GnT2",ENSG00000140297,"Glucosaminyl (N-acetyl) transferase 3, mucin type",15,59594875-59640239,"Enzymes, Predicted membrane proteins",Evidence at protein level,HPA011154,Enhanced,,Approved,Golgi apparatus<br>Vesicles,"Liver cancer:6.49e-5 (unfavourable), Endometrial cancer:1.78e-4 (favourable)",Tissue enhanced,Tissue enhanced,,colon: 142.2;gallbladder: 118.0;rectum: 134.6;small intestine: 138.4,duodenum: 97.7,Cell line enriched,6.0,A549: 133.3
43,GEM,KIR,ENSG00000164949,GTP binding protein overexpressed in skeletal muscle,8,94249253-94262350,Predicted intracellular proteins,Evidence at protein level,HPA024798,Approved,,,,"Renal cancer:1.56e-5 (unfavourable), Thyroid cancer:4.29e-4 (unfavourable)",Expressed in all,Tissue enhanced,,gallbladder: 364.8,endometrium: 157.2,Cell line enhanced,,BJ hTERT+: 67.0;U-266/70: 106.3;U-87 MG: 102.0
44,GLP2R,,ENSG00000065325,Glucagon like peptide 2 receptor,17,9822206-9892102,"FDA approved drug targets, G-protein coupled receptors, Predicted membrane proteins",Evidence at protein level,"CAB022690, HPA049244",Supported,,Supported,Plasma membrane,,Tissue enhanced,Tissue enhanced,,gallbladder: 19.3,duodenum: 10.1,Cell line enhanced,,A549: 15.1;HeLa: 54.7;SiHa: 8.7
45,GPBAR1,"BG37, GPCR, GPCR19, GPR131, M-BAR, MGC40597, TGR5",ENSG00000179921,G protein-coupled bile acid receptor 1,2,218259496-218263859,"G-protein coupled receptors, Predicted membrane proteins, Transporters",Evidence at protein level,HPA062890,Enhanced,,,,,Tissue enhanced,Tissue enhanced,,gallbladder: 26.9;smooth muscle: 14.0,adipose tissue: 9.9,Cell line enhanced,,HHSteC: 1.5;SCLC-21H: 1.1;U-937: 1.4
46,GPX2,GSHPX-GI,ENSG00000176153,Glutathione peroxidase 2,14,64939152-64942905,"Cancer-related genes, Enzymes, Predicted intracellular proteins",Evidence at protein level,HPA003545,Enhanced,,Approved,Nucleoplasm<br>Cytosol,Head and neck cancer:5.10e-4 (unfavourable),Mixed,Tissue enhanced,,gallbladder: 696.1;rectum: 461.1,stomach: 334.9,Group enriched,20.0,A549: 930.0;HaCaT: 249.8;Hep G2: 659.7;RT4: 543.6;SCLC-21H: 352.2
47,GREM1,"CKTSF1B1, CRAC1, DAND2, DRM, gremlin, HMPS",ENSG00000166923,"Gremlin 1, DAN family BMP antagonist",15,32717974-32745107,"Disease related genes, Predicted secreted proteins",Evidence at protein level,HPA007526,Uncertain,,,,Lung cancer:4.46e-4 (unfavourable),Tissue enhanced,Tissue enhanced,,gallbladder: 92.4;smooth muscle: 67.3,urinary bladder: 22.4,Cell line enhanced,,BJ: 150.1;BJ hTERT+: 219.5;BJ hTERT+ SV40 Large T+ RasG12V: 161.4;fHDF/TERT166: 426.8;hTEC/SVTERT24-B: 168.1
48,GREM2,"CKTSF1B2, DAND3, FLJ21195, Prdc",ENSG00000180875,"Gremlin 2, DAN family BMP antagonist",1,240489573-240612149,"Disease related genes, Predicted secreted proteins",Evidence at protein level,CAB009920,Uncertain,,,,,Mixed,Tissue enhanced,,gallbladder: 48.8;parathyroid gland: 78.3,rectum: 22.6,Cell line enhanced,,BJ: 5.1;BJ hTERT+: 5.2;fHDF/TERT166: 25.0
49,HNF1B,"HNF1beta, LFB3, MODY5, TCF2, VHNF1",ENSG00000275410,HNF1 homeobox B,17,37686432-37745247,"Disease related genes, Predicted intracellular proteins, Transcription factors",Evidence at protein level,"HPA002083, CAB068192",Enhanced,,Supported,Nucleoplasm,"Urothelial cancer:2.51e-6 (favourable), Renal cancer:6.00e-4 (favourable)",Tissue enhanced,Tissue enhanced,,gallbladder: 21.5;kidney: 25.3,lung: 9.6,Cell line enhanced,,A549: 16.8;CACO-2: 17.9;EFO-21: 26.2;RPTEC TERT1: 95.5
50,HS3ST1,3OST1,ENSG00000002587,Heparan sulfate-glucosamine 3-sulfotransferase 1,4,11393150-11429765,"Enzymes, Predicted secreted proteins",Evidence at protein level,HPA002237,Approved,,Approved,Vesicles,"Renal cancer:5.99e-8 (favourable), Endometrial cancer:7.73e-4 (favourable), Urothelial cancer:8.67e-4 (favourable)",Mixed,Tissue enhanced,,gallbladder: 13.9;ovary: 23.2,urinary bladder: 5.6,Cell line enhanced,,CAPAN-2: 12.2;RPTEC TERT1: 9.1;RT4: 8.0;SCLC-21H: 4.3
51,IL11,"AGIF, IL-11",ENSG00000095752,Interleukin 11,19,55364389-55370463,"Cancer-related genes, Predicted intracellular proteins, Predicted secreted proteins",Evidence at protein level,HPA044955,,,Uncertain,Mitochondria,Pancreatic cancer:7.50e-4 (unfavourable),Mixed,Tissue enhanced,,appendix: 5.7;endometrium: 5.2;gallbladder: 4.9,placenta: 1.7,Cell line enhanced,,BJ: 50.3;BJ hTERT+: 54.5;hTEC/SVTERT24-B: 54.2;U-251 MG: 179.7
52,INHBA,,ENSG00000122641,Inhibin beta A subunit,7,41667168-41705834,"Cancer-related genes, Candidate cardiovascular disease genes, Plasma proteins, Predicted secreted proteins",Evidence at protein level,,,,,,"Renal cancer:7.91e-8 (unfavourable), Cervical cancer:1.46e-5 (unfavourable), Head and neck cancer:4.34e-4 (unfavourable), Lung cancer:7.72e-4 (unfavourable)",Expressed in all,Tissue enhanced,,endometrium: 28.7;gallbladder: 35.1,lung: 16.4,Group enriched,6.0,HBEC3-KT: 54.3;hTEC/SVTERT24-B: 227.2;hTERT-HME1: 71.4;TIME: 97.6;U-138 MG: 172.4;U-2 OS: 52.9
53,ITGBL1,"OSCP, TIED",ENSG00000198542,Integrin subunit beta like 1,13,101452593-101720856,"Predicted intracellular proteins, Predicted secreted proteins",Evidence at protein level,HPA005676,Uncertain,,,,Urothelial cancer:2.70e-4 (unfavourable),Mixed,Tissue enhanced,,gallbladder: 59.8,placenta: 47.2,Cell line enhanced,,ASC diff: 142.9;fHDF/TERT166: 267.4;LHCN-M2: 259.5
54,KCNS1,Kv9.1,ENSG00000124134,Potassium voltage-gated channel modifier subfamily S member 1,20,45092310-45101112,"Predicted membrane proteins, Transporters, Voltage-gated ion channels",Evidence at protein level,,,,,,Ovarian cancer:6.45e-4 (unfavourable),Tissue enhanced,Tissue enhanced,,cerebral cortex: 9.3;gallbladder: 3.8;seminal vesicle: 4.2,testis: 1.7,Cell line enhanced,,HBF TERT88: 1.3;HHSteC: 1.8;THP-1: 1.2;U-87 MG: 3.0
55,KERA,"CNA2, SLRR2B",ENSG00000139330,Keratocan,12,91050491-91057983,"Disease related genes, Predicted secreted proteins",Evidence at protein level,HPA039321,Uncertain,,,,,Mixed,Tissue enhanced,,gallbladder: 1.5,"breast,fallopian tube: 0.8",Not detected,,
56,KIF12,,ENSG00000136883,Kinesin family member 12,9,114086126-114099291,Predicted intracellular proteins,Evidence at protein level,"HPA020192, HPA024127",Uncertain,,Approved,Nucleoplasm,,Mixed,Tissue enhanced,,gallbladder: 36.6;kidney: 46.9,thyroid gland: 33.0,Cell line enhanced,,CACO-2: 6.3;RPTEC TERT1: 31.9;SCLC-21H: 7.6
57,LCN2,"24p3, NGAL",ENSG00000148346,Lipocalin 2,9,128149071-128153455,"Candidate cardiovascular disease genes, Plasma proteins, Predicted secreted proteins",Evidence at protein level,"HPA002695, CAB016549, CAB016550",Enhanced,,Supported,Endoplasmic reticulum,Breast cancer:9.61e-4 (favourable),Mixed,Tissue enhanced,,bone marrow: 1852.1;gallbladder: 3419.4,"cervix, uterine: 1163.5",Group enriched,11.0,CAPAN-2: 3169.5;EFO-21: 1362.3
58,LGALS2,HL14,ENSG00000100079,Galectin 2,22,37570246-37582616,Predicted intracellular proteins,Evidence at protein level,"HPA003536, CAB025198",Enhanced,,Approved,Nucleoplasm<br>Mitochondria,,Expressed in all,Tissue enhanced,,gallbladder: 537.1;small intestine: 225.0,kidney: 155.6,Group enriched,13.0,CACO-2: 92.0;Hep G2: 42.9
59,LGALS9B,,ENSG00000170298,Galectin 9B,17,20449395-20467539,Predicted intracellular proteins,Evidence at protein level,"HPA046876, HPA047218",Approved,,Uncertain,Cytosol,,Mixed,Tissue enhanced,,gallbladder: 11.7;rectum: 11.8;stomach: 28.8,colon: 7.5,Group enriched,7.0,CAPAN-2: 7.5;U-937: 2.2
60,LGALS9C,,ENSG00000171916,Galectin 9C,17,18476737-18494945,Predicted intracellular proteins,Evidence at protein level,"HPA046876, HPA047218",Approved,,Approved,Cytosol,,Mixed,Tissue enhanced,,gallbladder: 4.9;rectum: 5.0;stomach: 10.0,colon: 2.7,Not detected,,
61,LIF,"CDF, DIA, HILDA",ENSG00000128342,Leukemia inhibitory factor,22,30240447-30246851,"Cancer-related genes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins",Evidence at protein level,"HPA018844, CAB025985",Approved,,Enhanced,Cytosol,"Renal cancer:6.78e-8 (unfavourable), Cervical cancer:9.01e-4 (unfavourable)",Expressed in all,Tissue enhanced,,gallbladder: 75.6,urinary bladder: 42.0,Cell line enhanced,,hTEC/SVTERT24-B: 111.9;U-138 MG: 121.7;U-251 MG: 77.3;U-87 MG: 95.4
62,LMO7DN,C13orf45,ENSG00000178734,LMO7 downstream neighbor,13,75871038-75883811,Predicted intracellular proteins,Evidence at transcript level,HPA052013,Uncertain,,,,,Not detected,Tissue enhanced,,gallbladder: 1.3,"esophagus,lung,testis: 0.7",Cell line enhanced,,LHCN-M2: 1.1
63,LUM,"LDC, SLRR2D",ENSG00000139329,Lumican,12,91102629-91111831,"Cancer-related genes, Plasma proteins, Predicted secreted proteins",Evidence at protein level,"HPA001522, CAB025783",Supported,,,,Renal cancer:1.75e-6 (unfavourable),Expressed in all,Tissue enhanced,,gallbladder: 929.5,placenta: 602.2,Cell line enhanced,,BJ: 269.9;BJ hTERT+: 1272.0;fHDF/TERT166: 208.2
64,LYPD6,MGC52057,ENSG00000187123,LY6/PLAUR domain containing 6,2,149329985-149474148,Predicted secreted proteins,Evidence at protein level,HPA042805,Uncertain,,Approved,Cytosol,"Urothelial cancer:2.72e-4 (favourable), Ovarian cancer:3.59e-4 (favourable)",Mixed,Tissue enhanced,,gallbladder: 17.3;placenta: 22.5,breast: 12.0,Cell line enhanced,,AN3-CA: 33.5;fHDF/TERT166: 36.6;LHCN-M2: 38.4;RT4: 30.7
65,LYPD6B,"CT116, LYPD7",ENSG00000150556,LY6/PLAUR domain containing 6B,2,149038107-149215262,"Predicted secreted proteins, Transporters",Evidence at transcript level,HPA049239,Uncertain,,,,,Mixed,Tissue enhanced,,gallbladder: 58.6;skin: 56.5,testis: 42.4,Cell line enhanced,,fHDF/TERT166: 50.2;LHCN-M2: 85.2;RT4: 43.6
66,MFAP2,"MAGP, MAGP-1",ENSG00000117122,Microfibrillar associated protein 2,1,16974502-16980835,Predicted secreted proteins,Evidence at protein level,HPA007354,Enhanced,,,,Renal cancer:2.52e-8 (unfavourable),Expressed in all,Tissue enhanced,,gallbladder: 100.7,endometrium: 82.4,Cell line enhanced,,HUVEC TERT2: 193.6;SH-SY5Y: 203.2
67,MMP1,CLG,ENSG00000196611,Matrix metallopeptidase 1,11,102789920-102798160,"Cancer-related genes, Candidate cardiovascular disease genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted secreted proteins",Evidence at protein level,HPA004920,,,Approved,Vesicles,"Renal cancer:9.86e-10 (unfavourable), Liver cancer:4.22e-6 (unfavourable), Cervical cancer:4.66e-4 (unfavourable)",Tissue enhanced,Tissue enhanced,,appendix: 39.2;gallbladder: 126.4,urinary bladder: 29.1,Cell line enhanced,,BJ hTERT+: 921.1;HBF TERT88: 1061.5;HUVEC TERT2: 2464.5;WM-115: 1436.5
68,MMP19,"MMP18, RASI-1",ENSG00000123342,Matrix metallopeptidase 19,12,55835433-55842966,"Disease related genes, Enzymes, FDA approved drug targets, Predicted secreted proteins",Evidence at protein level,HPA070804,,,Approved,Endoplasmic reticulum<br>Vesicles,Renal cancer:8.56e-9 (unfavourable),Expressed in all,Tissue enhanced,,adipose tissue: 64.2;gallbladder: 97.3,placenta: 28.2,Cell line enriched,7.0,BEWO: 141.1
69,MMP2,"CLG4, CLG4A, TBE-1",ENSG00000087245,Matrix metallopeptidase 2,16,55389700-55506691,"Cancer-related genes, Candidate cardiovascular disease genes, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins",Evidence at protein level,"HPA001939, CAB002788",Approved,,Uncertain,Vesicles<br>Cytosol,,Expressed in all,Tissue enhanced,,gallbladder: 1682.1,urinary bladder: 910.7,Cell line enhanced,,ASC diff: 3859.6;U-138 MG: 1525.4;U-87 MG: 1772.5
70,MMP7,"MPSL1, PUMP-1",ENSG00000137673,Matrix metallopeptidase 7,11,102520508-102530753,"Cancer-related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted secreted proteins",Evidence at protein level,"CAB025869, HPA051358",Supported,,Approved,Nucleoplasm<br>Vesicles,"Liver cancer:2.53e-4 (unfavourable), Lung cancer:3.38e-4 (unfavourable)",Expressed in all,Tissue enhanced,,gallbladder: 820.8,breast: 201.7,Cell line enhanced,,A549: 133.0;CAPAN-2: 715.3;EFO-21: 178.3;RPTEC TERT1: 262.4
71,MPP6,"p55T, PALS2, VAM-1",ENSG00000105926,Membrane palmitoylated protein 6,7,24573268-24694193,Predicted intracellular proteins,Evidence at protein level,"HPA019085, HPA020456",Enhanced,,,,"Renal cancer:3.05e-5 (favourable), Head and neck cancer:8.85e-5 (unfavourable), Endometrial cancer:1.46e-4 (unfavourable), Thyroid cancer:5.28e-4 (unfavourable)",Expressed in all,Tissue enhanced,,gallbladder: 29.9;testis: 45.3,cerebral cortex: 14.9,Expressed in all,,
72,MUC3A,MUC3,ENSG00000169894,"Mucin 3A, cell surface associated",7,100949555-100968346,"Predicted membrane proteins, Predicted secreted proteins",Evidence at protein level,HPA010871,Uncertain,,,,,Tissue enhanced,Tissue enhanced,,duodenum: 41.6;gallbladder: 21.8;small intestine: 37.1,rectum: 13.1,Cell line enhanced,,CACO-2: 6.0;CAPAN-2: 2.1;U-2 OS: 1.4
73,NCMAP,"C1orf130, FLJ42528, MP11",ENSG00000184454,Non-compact myelin associated protein,1,24556111-24609328,Predicted membrane proteins,Evidence at transcript level,HPA013656,Uncertain,,,,Endometrial cancer:2.83e-6 (favourable),Mixed,Tissue enhanced,,gallbladder: 11.5,thyroid gland: 7.1,Cell line enhanced,,A549: 1.8;T-47d: 3.7;U-266/70: 2.3
74,OLFML2B,DKFZP586L151,ENSG00000162745,Olfactomedin like 2B,1,161983192-162023854,"Predicted intracellular proteins, Predicted secreted proteins",Evidence at protein level,"HPA054136, HPA062739",Approved,,Approved,Cytosol,"Renal cancer:1.01e-12 (unfavourable), Liver cancer:4.67e-4 (unfavourable)",Expressed in all,Tissue enhanced,,gallbladder: 76.9,placenta: 58.7,Cell line enhanced,,HSkMC: 82.6;RH-30: 85.9
75,ONECUT2,OC-2,ENSG00000119547,One cut homeobox 2,18,57435685-57491297,"Predicted intracellular proteins, Transcription factors",Evidence at protein level,HPA057058,Enhanced,,Supported,Nucleoplasm<br>Actin filaments,,Group enriched,Tissue enhanced,,duodenum: 10.4;gallbladder: 16.3,liver: 4.5,Cell line enhanced,,HDLM-2: 19.1;HeLa: 8.5;SCLC-21H: 12.1
76,PLD1,,ENSG00000075651,Phospholipase D1,3,171600405-171810950,"Enzymes, Plasma proteins, Predicted intracellular proteins, RAS pathway related proteins",Evidence at protein level,"CAB004527, HPA042396",Enhanced,,Approved,Plasma membrane,Urothelial cancer:4.76e-6 (unfavourable),Expressed in all,Tissue enhanced,,gallbladder: 138.3,small intestine: 49.2,Cell line enhanced,,HUVEC TERT2: 49.2;TIME: 42.2
77,PLPP4,"DPPL2, PPAPDC1, PPAPDC1A",ENSG00000203805,Phospholipid phosphatase 4,10,120456954-120589855,"Enzymes, Predicted membrane proteins",Evidence at protein level,HPA045188,Approved,,Approved,Nucleus<br>Nucleoli,,Mixed,Tissue enhanced,,cerebral cortex: 17.1;gallbladder: 10.4;testis: 12.7,kidney: 7.8,Cell line enhanced,,BJ: 30.3;U-251 MG: 92.6
78,PODN,"MGC24995, PCAN, PODOCAN, SLRR5A",ENSG00000174348,Podocan,1,53062052-53085502,Predicted intracellular proteins,Evidence at protein level,,,,,,"Renal cancer:2.02e-5 (unfavourable), Endometrial cancer:1.54e-4 (unfavourable)",Expressed in all,Tissue enhanced,,gallbladder: 161.0,ovary: 107.6,Cell line enhanced,,BJ: 33.5;fHDF/TERT166: 18.5;HHSteC: 78.9;U-2197: 43.8
79,PRDM6,"KMT8C, PRISM",ENSG00000061455,PR/SET domain 6,5,123089121-123194266,"Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Transcription factors",Evidence at protein level,"HPA030322, HPA030324",Uncertain,,Uncertain,Nucleoplasm,,Mixed,Tissue enhanced,,gallbladder: 5.2;placenta: 5.9,lung: 4.0,Cell line enhanced,,BEWO: 3.5;HEK93: 4.7
80,RDH12,"FLJ30273, LCA13, RP53, SDR7C2",ENSG00000139988,Retinol dehydrogenase 12 (all-trans/9-cis/11-cis),14,67701886-67734452,"Disease related genes, Plasma proteins, Predicted secreted proteins",Evidence at protein level,,,,,,,Mixed,Tissue enhanced,,gallbladder: 27.7;skin: 58.2,kidney: 13.6,Not detected,,
81,RNF183,MGC4734,ENSG00000165188,Ring finger protein 183,9,113297093-113303376,"Enzymes, Predicted membrane proteins",Evidence at protein level,HPA057675,Uncertain,,,,"Endometrial cancer:7.95e-6 (favourable), Renal cancer:3.51e-4 (favourable)",Tissue enhanced,Tissue enhanced,,epididymis: 20.0;gallbladder: 9.0,kidney: 4.3,Cell line enriched,10.0,SCLC-21H: 22.2
82,RP5-877J2.1,,ENSG00000250424,,7,30852273-30923812,Predicted membrane proteins,Evidence at protein level,"HPA019206, HPA030130",Approved,,Approved,Plasma membrane,,Not detected,Tissue enhanced,,gallbladder: 1.5,fallopian tube: 1.2,Not detected,,
83,SERPINA4,"KAL, kallistatin, KLST, KST, PI4",ENSG00000100665,Serpin family A member 4,14,94561091-94569913,"Plasma proteins, Predicted secreted proteins",Evidence at protein level,HPA003607,Approved,,,,Endometrial cancer:2.95e-4 (favourable),Group enriched,Tissue enhanced,,gallbladder: 72.6;liver: 242.7,epididymis: 42.8,Group enriched,36.0,CACO-2: 4.7;Hep G2: 16.4
84,SERPINE1,"PAI, PAI1, PLANH1",ENSG00000106366,Serpin family E member 1,7,101127089-101139266,"Cancer-related genes, Candidate cardiovascular disease genes, Disease related genes, FDA approved drug targets, Plasma proteins, Predicted secreted proteins",Evidence at protein level,"HPA050039, CAB068501",Uncertain,,Approved,Cytosol,"Renal cancer:5.88e-8 (unfavourable), Stomach cancer:3.27e-6 (unfavourable), Lung cancer:4.41e-6 (unfavourable), Head and neck cancer:2.84e-5 (unfavourable), Colorectal cancer:2.82e-4 (unfavourable), Cervical cancer:5.01e-4 (unfavourable), Urothelial cancer:5.51e-4 (unfavourable)",Expressed in all,Tissue enhanced,,gallbladder: 580.3;placenta: 600.2,adipose tissue: 215.8,Cell line enhanced,,TIME: 8072.1;U-138 MG: 4492.2;U-251 MG: 3465.4
85,SFRP2,"FRP-2, SARP1, SDF-5",ENSG00000145423,Secreted frizzled related protein 2,4,153780592-153789120,Predicted secreted proteins,Evidence at protein level,HPA002652,,,Approved,Intermediate filaments,"Renal cancer:8.56e-6 (unfavourable), Urothelial cancer:4.39e-4 (unfavourable)",Expressed in all,Tissue enhanced,,gallbladder: 489.6;urinary bladder: 512.1,esophagus: 234.0,Cell line enhanced,,AF22: 221.7;ASC diff: 57.2;HSkMC: 100.0;NTERA-2: 312.3
86,SLC1A7,EAAT5,ENSG00000162383,Solute carrier family 1 member 7,1,53087179-53142632,"Predicted membrane proteins, Transporters",Evidence at protein level,HPA049124,Supported,,,,,Tissue enhanced,Tissue enhanced,,gallbladder: 8.5,small intestine: 3.5,Cell line enriched,8.0,HHSteC: 21.0
87,SLC28A3,CNT3,ENSG00000197506,Solute carrier family 28 member 3,9,84275457-84340683,"Predicted membrane proteins, Transporters",Evidence at protein level,"HPA023311, HPA024729",Approved,,,,Breast cancer:3.37e-4 (favourable),Mixed,Tissue enhanced,,breast: 10.7;gallbladder: 11.7;skin: 9.8,bone marrow: 6.2,Cell line enriched,8.0,HMC-1: 51.9
88,SLC38A11,"AVT2, FLJ39822",ENSG00000169507,Solute carrier family 38 member 11,2,164896186-164955525,"Predicted membrane proteins, Transporters",Evidence at transcript level,HPA043432,Uncertain,,,,Renal cancer:2.00e-8 (favourable),Tissue enriched,Tissue enhanced,,epididymis: 47.1;gallbladder: 28.2,seminal vesicle: 23.5,Cell line enriched,8.0,BJ hTERT+: 202.7
89,SLC9A3,NHE3,ENSG00000066230,Solute carrier family 9 member A3,5,473310-524332,"Disease related genes, Potential drug targets, Predicted membrane proteins, Transporters",Evidence at protein level,"HPA036493, HPA036669",Enhanced,,Supported,Plasma membrane,Melanoma:8.49e-4 (unfavourable),Mixed,Tissue enhanced,,colon: 80.9;gallbladder: 66.1;small intestine: 72.6,kidney: 57.3,Cell line enhanced,,HDLM-2: 30.4
90,SNAI1,"SLUGH2, SNA, SNAH, SNAIL, SNAIL1",ENSG00000124216,Snail family transcriptional repressor 1,20,49982999-49988886,"Predicted intracellular proteins, Transcription factors",Evidence at protein level,"CAB005883, HPA056831, HPA069985, CAB078687",Supported,,Supported,Nucleus<br>Cytosol,"Renal cancer:2.63e-7 (unfavourable), Thyroid cancer:8.82e-7 (unfavourable), Lung cancer:1.61e-5 (unfavourable), Colorectal cancer:4.76e-4 (unfavourable)",Expressed in all,Tissue enhanced,,gallbladder: 26.2,thyroid gland: 13.4,Cell line enhanced,,SiHa: 30.1;TIME: 32.4;WM-115: 25.0
91,SPON1,"f-spondin, KIAA0762",ENSG00000262655,Spondin 1,11,13962689-14267884,"Plasma proteins, Predicted secreted proteins",Evidence at protein level,"HPA038584, HPA077546",Approved,,Approved,Nucleus<br>Nucleoli<br>Actin filaments<br>Microtubule ends<br>Cytokinetic bridge,"Urothelial cancer:1.88e-4 (unfavourable), Renal cancer:3.12e-4 (favourable)",Expressed in all,Tissue enhanced,,gallbladder: 167.6,fallopian tube: 104.8,Group enriched,39.0,EFO-21: 209.9;RPTEC TERT1: 476.8
92,SPP1,"BNSP, BSPI, ETA-1, OPN",ENSG00000118785,Secreted phosphoprotein 1,4,87975650-87983426,"Cancer-related genes, Plasma proteins, Predicted secreted proteins",Evidence at protein level,"CAB002212, HPA027540, HPA027541",Enhanced,,Supported,Golgi apparatus,"Liver cancer:2.84e-6 (unfavourable), Pancreatic cancer:5.89e-4 (unfavourable), Cervical cancer:9.52e-4 (unfavourable)",Expressed in all,Tissue enhanced,,gallbladder: 3987.0;kidney: 2404.4;placenta: 4045.7,cerebral cortex: 795.2,Group enriched,6.0,EFO-21: 4669.3;Hep G2: 1742.5;RPTEC TERT1: 8242.5
93,SULT1C4,"SULT1C, SULT1C2",ENSG00000198075,Sulfotransferase family 1C member 4,2,108377911-108388057,Predicted intracellular proteins,Evidence at protein level,HPA034530,,,Approved,Cytosol,Renal cancer:9.99e-7 (favourable),Group enriched,Tissue enhanced,,gallbladder: 41.5,ovary: 31.2,Cell line enhanced,,AF22: 8.6;HUVEC TERT2: 7.8;SH-SY5Y: 42.4
94,SYT13,KIAA1427,ENSG00000019505,Synaptotagmin 13,11,45240301-45286319,Predicted intracellular proteins,Evidence at protein level,"HPA046224, HPA056602",Uncertain,,Supported,Vesicles,Endometrial cancer:7.79e-5 (unfavourable),Mixed,Tissue enhanced,,cerebral cortex: 69.9;gallbladder: 32.9,small intestine: 14.4,Group enriched,9.0,A549: 17.3;NTERA-2: 8.8;RPTEC TERT1: 43.3;SCLC-21H: 17.8
95,TBC1D3E,,ENSG00000278599,TBC1 domain family member 3E,17,38127951-38138862,Predicted membrane proteins,Evidence at protein level,"HPA046969, HPA047745, HPA052553",Approved,,Uncertain,Vesicles,,Not detected,Tissue enhanced,,bone marrow: 1.1;gallbladder: 1.8;testis: 3.1,lymph node: 0.9,Cell line enhanced,,HHSteC: 3.4
96,TCN1,"TC1, TCI",ENSG00000134827,Transcobalamin 1,11,59852800-59866575,"Plasma proteins, Predicted secreted proteins",Evidence at protein level,,,,,,"Renal cancer:1.56e-8 (unfavourable), Breast cancer:1.90e-4 (favourable)",Tissue enhanced,Tissue enhanced,,bone marrow: 123.8;gallbladder: 254.4;salivary gland: 315.5,stomach: 75.5,Cell line enhanced,,CAPAN-2: 4.7;HaCaT: 4.6;PC-3: 6.4;SiHa: 7.7
97,THBS2,TSP2,ENSG00000186340,Thrombospondin 2,6,169215780-169254044,"Cancer-related genes, Disease related genes, Plasma proteins, Predicted secreted proteins",Evidence at protein level,"CAB017716, HPA044304",Approved,,Approved,Nuclear speckles<br>Plasma membrane<br>Cytosol,Renal cancer:3.77e-6 (unfavourable),Expressed in all,Tissue enhanced,,gallbladder: 113.4,endometrium: 71.2,Cell line enhanced,,ASC diff: 282.6;ASC TERT1: 196.5;BJ hTERT+ SV40 Large T+ RasG12V: 134.9;hTEC/SVTERT24-B: 150.4
98,TNFAIP6,"TSG-6, TSG6",ENSG00000123610,TNF alpha induced protein 6,2,151357592-151380048,"Plasma proteins, Predicted secreted proteins",Evidence at protein level,"CAB032719, HPA050884",Approved,,,,"Cervical cancer:8.18e-5 (unfavourable), Urothelial cancer:9.16e-5 (unfavourable), Renal cancer:5.59e-4 (unfavourable)",Tissue enhanced,Tissue enhanced,,appendix: 38.7;gallbladder: 31.8,adipose tissue: 18.7,Cell line enhanced,,BJ hTERT+: 54.6;HHSteC: 33.8;hTEC/SVTERT24-B: 54.8;U-2197: 41.1
99,TNFSF18,"AITRL, hGITRL, TL6",ENSG00000120337,Tumor necrosis factor superfamily member 18,1,173039960-173050963,Predicted membrane proteins,Evidence at protein level,,,,,,,Mixed,Tissue enhanced,,cerebral cortex: 2.8;gallbladder: 3.0,parathyroid gland: 1.4,Group enriched,11.0,EFO-21: 48.3;HUVEC TERT2: 65.6;TIME: 89.7
100,TPSAB1,"TPS1, TPS2, TPSB1",ENSG00000172236,Tryptase alpha/beta 1,16,1240696-1242554,"Enzymes, Predicted intracellular proteins, Predicted secreted proteins",Evidence at protein level,"CAB016369, CAB022175, HPA049153, HPA049554",Supported,,,,Head and neck cancer:9.62e-6 (favourable),Mixed,Tissue enhanced,,gallbladder: 211.6,lung: 158.5,Cell line enriched,163.0,HMC-1: 3406.5
101,TPSB2,,ENSG00000197253,Tryptase beta 2 (gene/pseudogene),16,1227272-1230184,"Enzymes, Predicted secreted proteins",Evidence at protein level,"HPA049153, HPA049554",Supported,,,,,Mixed,Tissue enhanced,,gallbladder: 156.9,lung: 117.5,Cell line enriched,7.0,HMC-1: 262.0
102,TSLP,,ENSG00000145777,Thymic stromal lymphopoietin,5,111070062-111078024,"Predicted intracellular proteins, Predicted secreted proteins",Evidence at protein level,,,,,,,Mixed,Tissue enhanced,,gallbladder: 15.0,prostate: 10.4,Cell line enhanced,,ASC TERT1: 10.5;HHSteC: 14.4;hTEC/SVTERT24-B: 22.1;hTERT-HME1: 9.6;U-87 MG: 13.8
103,UGT1A8,UGT1H,ENSG00000242366,UDP glucuronosyltransferase family 1 member A8,2,233617645-233773310,"Enzymes, Predicted membrane proteins",Evidence at protein level,,,,,,,Tissue enhanced,Tissue enhanced,,colon: 16.0;gallbladder: 10.3;rectum: 9.7;urinary bladder: 22.7,small intestine: 4.9,Cell line enriched,53.0,RT4: 96.7
104,UGT2A3,FLJ21934,ENSG00000135220,UDP glucuronosyltransferase family 2 member A3,4,68928463-68951791,"Enzymes, Predicted membrane proteins",Evidence at protein level,HPA045108,Supported,,,,"Renal cancer:6.07e-7 (favourable), Colorectal cancer:3.31e-4 (favourable)",Tissue enriched,Tissue enhanced,,duodenum: 82.1;gallbladder: 46.3;kidney: 46.8;small intestine: 85.9,rectum: 23.9,Cell line enriched,8.0,Hep G2: 13.5
105,WNT7A,,ENSG00000154764,Wnt family member 7A,3,13816258-13880121,"Disease related genes, Plasma proteins, Predicted intracellular proteins",Evidence at protein level,"HPA015719, CAB025894",Approved,,,,"Pancreatic cancer:3.03e-6 (unfavourable), Endometrial cancer:2.96e-5 (unfavourable)",Tissue enhanced,Tissue enhanced,,cerebral cortex: 6.7;gallbladder: 3.6;placenta: 3.9,lung: 3.0,Group enriched,5.0,BEWO: 56.9;EFO-21: 52.0;PC-3: 18.2;RPTEC TERT1: 74.6
106,ZPLD1,,ENSG00000170044,Zona pellucida like domain containing 1,3,102099244-102479841,Predicted membrane proteins,Evidence at transcript level,HPA077519,,,Approved,Nucleoplasm,,Mixed,Tissue enhanced,,gallbladder: 3.5;testis: 1.3,duodenum: 0.9,Cell line enriched,8.0,RPTEC TERT1: 5.0
